20170419 TG Appointments Board EN
Author: alcyon
Transgene and Institut Bergonié Start the Phase 2 Part of the METROmaJX Trial
20170412 PR Metro-JX Ph2 EN
Transgene Announces Upcoming Investor Meetings and R&D Day
20170410 PR Next investor events
Local and Abscopal Effects in Oncolytic Virotherapy are boosted by Immune Checkpoint Blockade, Immunogenic Chemotherapy, or IFNAR blockade
Laetitia Fend, et al. AACR, American Association for cancer Research, April 2017 Download the poster here Poster Presentation
Transgene Presents Very Promising New Immunology Data of its Next Generation Armed Oncolytic Virus at the AACR Annual Meeting in Washington, DC
20170330-AACR poster EN
Major achievements in 2016 validate Transgene’s strategy and provide promising outlook for 2017
20170320 2016 Resultats annuels EN
First Patient dosed in Phase 2 Trial Evaluating Transgene’s TG4010 in Combination with Opdivo® (nivolumab) for 2nd Line Treatment of Metastatic Non-Small Cell Lung Cancer (NSCLC)
20170313 FPI Kelly study EN
Vectorized gene therapy of liver tumors: proof-of-concept of TG4023 (MVA-FCU1) in combination with flucytosine
Faleh Husseini, et al. Annals of Oncology, February 2017, DOI: https://doi.org/10.1093/annonc/mdw440 – Download the article Publication TG4023 is a non-replicative MVA integrating the FCU1 gene that has been inserted in the oncolytic virus TG6002.
Transgene and Léon Bérard Cancer Center Announce Dosing of the First Patient in a Phase 1 Immunotherapy Clinical Trial Evaluating the Intra-Tumoral Co-Administration of Pexa-Vec plus Ipilimumab (Yervoy®) in Solid Cancers
20170213 ISI-JX FPI EN final
Radiotherapy and MVA-MUC1-IL-2 vaccine act synergistically for inducing specific immunity to MUC-1 tumor antigen
Gilda G. Hillman, et al. Journal for ImmunoTherapy of Cancer, January 2017 – Download the article Publication